UBS raised the firm’s price target on Encompass Health (EHC) to $140 from $130 and keeps a Buy rating on the shares. Fundamentals remained strong in Q2, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC:
- Encompass Health Reports Strong Q2 2025 Results
- Encompass Health Reports Strong Q2 Earnings Growth
- Closing Bell Movers: Palantir hits record highs on beat and raise
- Encompass Health: Strong Financial Performance and Positive Outlook Justify Buy Rating Despite Stock Volatility
- Encompass Health Reports Strong Q2 2025 Financial Results